Compare NRSN & MBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NRSN | MBRX |
|---|---|---|
| Founded | 2017 | 2015 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.6M | 6.4M |
| IPO Year | 2021 | 2016 |
| Metric | NRSN | MBRX |
|---|---|---|
| Price | $1.25 | $7.60 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | $91.75 | ★ $240.00 |
| AVG Volume (30 Days) | ★ 40.8K | 35.7K |
| Earning Date | 09-25-2026 | 11-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.25 | $0.16 |
| 52 Week High | $7.50 | $10.24 |
| Indicator | NRSN | MBRX |
|---|---|---|
| Relative Strength Index (RSI) | 31.98 | 59.55 |
| Support Level | $0.70 | $2.12 |
| Resistance Level | $2.17 | $10.24 |
| Average True Range (ATR) | 0.24 | 0.73 |
| MACD | 0.02 | -0.36 |
| Stochastic Oscillator | 8.25 | 41.57 |
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.
Moleculin Biotech Inc is a late-stage pharmaceutical development company currently evaluating Annamycin, also known as L-Annamycin and by its generic name naxtarubicin. The company has two additional portfolios of technologies for hard-to-treat cancers and viruses with clinical and preclinical research funded by investigators at academic institutions. The Company operates in one reportable segment, which is the development and commercialization of drug products.